JAMA reports fluvoxamine as potential early treatment for COVID-19
A recent study published in JAMA found that fluvoxamine may prevent serious breathing problems in people with mild COVID-19 illness. The results show that fluvoxamine has the potential to reduce the risk of hospitalization in COVID-19 patients.